Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.
McDaniel JR. et al, (2025), J Exp Med, 222
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Venkatraman N. et al, (2025), Lancet Microbe, 6
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E.
Ali MS. et al, (2025), NPJ Vaccines, 10
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.
Stockdale LK. et al, (2025), NPJ Vaccines, 10
R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.
Kibwana E. et al, (2025), Front Immunol, 16
Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.
Bundi C. et al, (2025), Front Immunol, 16
Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults
Silman D. et al, (2024), Wellcome Open Research, 9, 734 - 734
R21/Matrix-M Protects Against Dermal but not Against Venous Parasites in Human Challenge Studies
Kapulu MC. et al, (2024)
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.
Hanboonkunupakarn B. et al, (2024), NPJ Vaccines, 9
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
Mentzer AJ. et al, (2024), Nat Med, 30, 1384 - 1394
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N. et al, (2024), Lancet Infect Dis, 24, 465 - 475
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS. et al, (2024), Lancet, 403, 533 - 544
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Jenkin D. et al, (2023), Lancet Infect Dis, 23, 956 - 964
Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria
Li K. et al, (2023), Biophysical journal, 122, 144a - 145a